Neurocrine Biosciences Inc
NASDAQ:NBIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
US |
|
Avery Dennison Corp
NYSE:AVY
|
US |
|
A
|
American Coastal Insurance Corp
NASDAQ:ACIC
|
US |
|
Vista Oil & Gas SAB de CV
NYSE:VIST
|
MX |
|
P
|
Pandora A/S
F:3P7
|
DK |
|
Future Supply Chain Solutions Ltd
NSE:FSC
|
IN |
|
R
|
Revenga Ingenieros SA
MAD:RSS
|
ES |
|
X
|
X5 Retail Group NV
MOEX:FIVE
|
RU |
|
Accuracy Shipping Ltd
NSE:ACCURACY
|
IN |
|
S
|
SMU SA
SGO:SMU
|
CL |
|
C
|
Converge Technology Solutions Corp
TSX:CTS
|
CA |
|
Fluent Inc
NASDAQ:FLNT
|
US |
|
Bimobject AB
F:BOJB
|
SE |
|
Victory Mines Ltd
ASX:VIC
|
AU |
|
Where Food Comes From Inc
NASDAQ:WFCF
|
US |
|
W
|
WindowMaster International A/S
F:9FF
|
DK |
Wall Street
Price Targets
NBIX Price Targets Summary
Neurocrine Biosciences Inc
According to Wall Street analysts, the average 1-year price target for
NBIX
is 179.79 USD
with a low forecast of 141.4 USD and a high forecast of 214.2 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is NBIX's stock price target?
Price Target
179.79
USD
According to Wall Street analysts, the average 1-year price target for
NBIX
is 179.79 USD
with a low forecast of 141.4 USD and a high forecast of 214.2 USD.
What is Neurocrine Biosciences Inc's Revenue forecast?
Projected CAGR
14%
For the last 14 years the
compound annual growth rate for
Neurocrine Biosciences Inc's revenue is
29%.
The projected
CAGR
for the next 3 years is
14%.
What is Neurocrine Biosciences Inc's Operating Income forecast?
Projected CAGR
27%
For the last 14 years the
compound annual growth rate for
Neurocrine Biosciences Inc's operating income is
23%.
The projected
CAGR
for the next 3 years is
27%.
What is Neurocrine Biosciences Inc's Net Income forecast?
Projected CAGR
30%
For the last 14 years the
compound annual growth rate for
Neurocrine Biosciences Inc's net income is
20%.
The projected
CAGR
for the next 3 years is
30%.
